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Abstract
Crohn’s disease is a chronic illness that may often follow a relapsing-remitting course. Many of the factors that may
be associated with the spontaneous remission of this disease (i.e. not related to specific treatment) remain to be
determined. In the present report, we review the medical history of a patient with a long history of moderate to
severe Crohn’s whose complete remission immediately followed the development of a febrile infection.
The patient first developed symptoms of Crohn’s in her late adolescent years. At the time of diagnosis at age 23,
she was placed on mesalamine - without effective control her disease symptoms. Due to progressive deterioration,
the patient underwent a bowel resection at age 25. Soon afterwards symptoms recurred, gradually increasing in
severity. In February 2005, at age 36, the patient developed a painful abscess associated with a rectal fistula. Other
symptoms at the time included chronic bone and stomach pain, swollen joints, and debilitating fatigue. Surgical
correction was scheduled in mid-March. In late February, the patient developed a respiratory infection associated
with fevers of 103-104°F. After the onset of fever, the abscess pain disappeared and this was soon followed by a
disappearance of all other disease symptoms. By the time the corrective surgery occurred, she had no Crohn’s
symptoms. Her remission lasted 10 weeks when the previous symptoms then reappeared. The patient has
subsequently used a variety of conventional therapies, but still suffers from severe symptoms of her disease.
In recent years, a growing body of literature has emphasized the important role that innate immunity plays in the
etiology of Crohn’s disease; however, a key component of innate immunity, the febrile response, has been
overlooked. Other cases of spontaneous remission following febrile infection in inflammatory bowel disease have
been reported. Moreover, induction of a febrile response was in the past used as a treatment for inflammatory
bowel disease, but was later replaced by surgery and corticosteroids. Further exploration of this arm of the innate
immune response may provide new opportunities for patients where conventional therapies fail to secure relief.
Background
Crohn’s disease is a chronic inflammatory disease of the
gastrointestinal tract that often follows a relapsing-
remitting course. Current treatment regimens for
Crohn’s disease focus on immunosuppressive agents
including aminosalicylates, corticosteroids, purine analo-
gues such as azathioprine or 6-mercaptopurine, and bio-
logic therapies such as tumor necrosis factor alpha
inhibitors. Along similar lines, surgery is frequently
employed to excise regions of immune-mediated inflam-
matory activity. Contrasting such approaches, recent
studies have suggested that underlying defects in innate
immunity may play a role in the development of this
disease [1,2]. Innate immune deficiencies may in turn
leave predisposed individuals vulnerable to an infection
or infections that cause the disease. In support of a role
for infection, various antibiotic [3] and probiotic [4]
regimens have been explored in an attempt to eradicate
or displace the suspect pathogen(s). Many pathogens
have been implicated with the idea that the disease may
result from some form of occult infection [5,6] or from
reduced control/decreased biodiversity of commensal
bacteria [7,8]. While the probiotic or antibiotic approach
may lead to a lessening of inflammation and symptoms,
the ability of such regimens to produce cures is limited
and antibiotic side effects prevent its long term use.
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innate immune response, the febrile response arm
remains a critical, but often ignored component of
innate immunity [9,10]. In the present case study, we
report on the temporary remission of severe Crohn’s
disease following an influenza-like illness with repeated
high fevers and review the literature associated with this
phenomenon.
Case presentation
The patient is a 40 year old female with lengthy history
of moderate to severe Crohn’s disease. The patient’s
family history included a father who was diagnosed with
Crohn’s disease at age 20. He later developed colon ade-
nocarcinoma at age 46 years, dying the following year
from his cancer.
The patient first developed symptoms of her disease in
college at age 18. Symptoms at the time included
abdominal pain, weight loss (15 lbs), and debilitating
fatigue. However, even previous to this time, the patient
suffered for many years from pain in her bones and
joints. During her college years, she continued to lose
weight. At age 23, following the onset of severe abdom-
inal pain and an inability to eat or drink, a diagnosis of
Crohn’s disease was finally made. The disease was found
to occupy the ileocaecal region. At that time, she began
treatment with mesalamine, although it was not effective
in controlling her symptoms.
At age 25, the patient presented with symptoms of
acute bowel obstruction. Surgery revealed volvulus of
the ileocaecal region and 10 inches of the distal ileum
and entire caecum were excised. Symptoms recurred
fairly soon afterward, but it was a further 6 to 7 years
before they became severe.
In February 2005, at age 36, the patient developed a
painful fistula-associated rectal abscess. At this time, the
patient’s ongoing symptoms included chronic bone and
abdominal pain, swollen joints, and debilitating fatigue.
On February 18th, she was placed on cephalexin to treat
the abscess previous to a scheduled surgery to correct
the fistula. Following a week with no improvement in
abscess pain while on the antibiotic, the patient then
developed an influenza-like infection (high fevers, chills,
headache, cough, and rhinorrhea). After the first onset
of fever, the abscess pain was no longer apparent. The
recurrent fevers (103-104°F) from the infection persisted
for four days and were associated with a complete disap-
pearance of all other disease symptoms. This was fol-
l o w e db ya ni n c r e a s ei na p p e t i t ea n dw e i g h t .O nM a r c h
18th, the patient underwent the scheduled surgery to
correct the fistula. Her energy level had been continually
improving and after a month she was running up to 3
miles a day and was able to run up hills that she could
n o te v e nw a l ku pp r i o rt oh e rr e m i s s i o n .A f t e r
approximately 10 weeks of this symptom-free remission,
her previous disease symptoms began to return. The
initial symptoms included hugely swollen knees and
diarrhea. The patient was again placed on cephalexin in
the expectation that it might result in another remission,
but the intervention had no effect on symptoms.
Since that remission, the patient subsequently used:
budesonide; triple antibiotic therapy; infliximab with
prednisone; and is presently on adalimumab with
methylprednisolone to treat swollen and painful joints.
The patient’s current symptoms include bone pain,
recurrent painful blisters on her hands, crusting and
bleeding of the external nares, oral ulceration, chronic
abdominal pain with periodic diarrhea, and swollen and
painful joints with occasional extreme pain and swelling.
Conclusions
In the present case, the patient was diagnosed with
Crohn’s 13 years before the infection-associated remis-
sion, although she was symptomatic with the disease at
least 17 years before this remission. The patient’so n l y
preceding remission was that following small bowel sur-
gery; otherwise the patient had never been symptom-
free and ever-present were symptoms including chronic
fatigue, bone and abdominal pain, painful and swollen
joints, blisters and ulceration and a poor appetite caus-
ing her to be chronically underweight. The patient con-
tinues to struggle with these many symptoms which
have not been effectively controlled despite intensive
medical management.
Lobel and colleagues reported on an interesting series
of four Crohn’s disease and one ulcerative colitis remis-
sion that followed febrile infections [11]. The patients’
fevers, usually high, were of two weeks or greater in
duration. In four of five cases, no etiology for the fever
could be determined, and in the fifth patient, the infec-
tion resulted from a perforation of an ileocolic anasto-
mosis and intraabdominal, perihepatic and
peripancreatic abscesses. None of the infections were
respiratory in nature. There were four females with
Crohn’s disease (age range 24 to 31 years) and one 34
year old male with ulcerative colitis. Reported remis-
sions were of 2-10 years in duration with no recurrences
at the time of reporting, although three subjects
remained on maintenance therapy subsequent to their
remissions. All patients were taking 6-mercaptopurine
(6MP) at the time of remission and the authors
hypothesized that fever along with 6MP-induced leuko-
penia was an important factor in the remissions.
A therapy to stimulate the innate febrile immune
response in inflammatory bowel disease dates back to
Arthur Hurst, who in 1921 [12] experimented with a
dysenteric bacterial serum therapy for one of his
patients with ulcerative colitis. Hurst would later report
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patient 15 years later [13]. Hurst, who subsequently
treated many more ulcerative colitis patients with this
therapy, summarized several of his notable findings [14].
First, he found that intramuscular injections were bene-
ficial, but less frequently than intravenous injections;
although he did raise the concern that an anaphylactic
reaction may occur following intravenous injection of
the vaccine. He further observed that rapid recovery was
most likely in the early stages of disease, but could occa-
sionally be very striking in long standing cases. Finally,
he noted that recurrence was much reduced if treatment
was continued until the sigmoidoscope shows no trace
of inflammation, even if symptoms had already disap-
peared for some weeks.
Based on the preliminary findings of Hurst, in the
1920s and 1930s Burrill Crohn (who first characterized
regional ileitis or Crohn’s disease [15]) experimented
using various intravenous therapies for the treatment of
ulcerative colitis. He stated that in approximately 45% of
cases there was a persistent cessation of symptoms and
restitution to a normal state. Crohn made some interest-
ing observations on the use of Hurst’si m m u n o t h e r a p y ,
which he used regardless of whether or not dysentery
organisms could be detected in a patient’s blood [16]:
“A severe febrile reaction was welcomed. A certain
degree of anaphylactic shock was regarded as more
beneficial than deleterious. The most beneficial
results were seen in those patients in whom the
intravenous injection of serum resulted in immediate
serum shock analogous to a non-specific protein
reaction and in those who showed late serum sick-
ness with urticaria and even joint manifestations.
The use of polyvalent anti-dysentery serum seemed
to give us best results.
In order to determine whether the effect of this
serum was a specific or a non-specific one, we
attempted, in a number of cases, to duplicate the
results by the intravenous injection of typhoid vac-
cine, such representing a convenient and direct
method of nonspecific protein therapy. Some fairly
good results were seen. Other miscellaneous meth-
ods of treatment were tried at various times in the
course of years, these methods including autogenous
vaccines of fecal organisms, Bargen’s serum and vac-
cine, transfusions, etc., some with good results,
many of them without any noticeable effect. It
would seem that among the various types of intrave-
nous therapy, no one item seemed to have a specific
effect upon the disease. It soon became obvious that
any protein agent which would produce a protein
shock and a febrile reaction, could bring about a
beneficial change in the chronic course of this
disease. The change from the slow, lethargic chroni-
city into a sudden flare-up induced by the protein
therapy of whatever type, frequently seemed to alter
the long drawn-out course of the malady. After sev-
eral severe protein shocks, the temperature would
frequently subside, diarrhea gradually and more
slowly diminish until constipation was achieved and
the general health of the patient, appetite, strength
and weight began to show steady improvement.”
Following World War II, new treatment options
became available including antibiotics and corticoster-
oids. By that time, Crohn had discontinued using bacter-
ial vaccines for his patients with inflammatory bowel
disease in preference to surgery, which initially seemed
to lead to a very high cure rate: “The percentage of sur-
gical cures is high, even when reckoned conservatively,
and it is grossly well over 80 per cent [17].” Although in
subsequent years, it became apparent to Crohn that
recurrences following surgery were not uncommon, and
similarly, other promising therapies failed to meet initial
expectations [18].
The possibility exists that other factors may have been
responsible for the patient’s remission. For example, the
antibiotic cephalexin could have played a role, although
some facts warrant against such a possibility. The
patient had been on cephalexin for many days without
any effect on her symptoms, and following disease
recurrence the rechallenge with cephalexin had no
impact on her symptoms. As to the surgery, by the time
the operation for her fistula had taken place, her
Crohn’s symptoms had already abated and therefore it
was an unlikely factor in her remission. In contrast to
the case series by Lobel, the acute infections that were
associated with remissions were of a longer duration
than in the present case; however, they also correspond-
ingly produced remissions of a much longer duration.
In the present case, the complete remission was unu-
sual for this patient due to a long history of severe and
poorly controlled disease. Moreover, the remission asso-
ciated with the patient’s febrile infection is analogous to
other reports of spontaneous or induced remissions fol-
lowing fever. In fact, the prompt improvement noted in
these reports, and in the present case, provides further
support for the hypothesis that the innate immune
response plays a key role - an adaptive immune
response would require a longer time period to develop.
Strategies that try to suppress the immune system or
those that try to eradicate or displace harmful bacteria
have shown limited efficacy. An alternative approach
would be to develop therapies that specifically activate
the innate febrile immune response, and thereby
attempt to reassert immune system control over patho-
gens or harmful indigenous flora.
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